Compare Stocks

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics	$0.69 -5.5%	$0.82	$0.50 ▼ $4.67	$40M	0.7	380,735 shs	363,035 shs
PZA Invesco National AMT-Free Municipal Bond ETF	$23.52 -0.4%	$23.81	$21.69 ▼ $24.28	$2.73B	0.12	875,856 shs	396,875 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	-5.72%	-14.88%	-22.47%	+22.12%	-83.57%
PZA Invesco National AMT-Free Municipal Bond ETF	-0.36%	+0.17%	-1.59%	-1.09%	+0.04%

Start loving Mondays like this (Ad)

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	3.9034 of 5 stars	3.4	2.0	0.0	4.2	2.0	1.7	1.3
PZA Invesco National AMT-Free Municipal Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	2.75	Moderate Buy	$9.75	1,313.04% Upside
PZA Invesco National AMT-Free Municipal Bond ETF	0.00	N/A	N/A	N/A

Current Analyst Ratings

Latest CARA and PZA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/28/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/6/2024	CARA Cara Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
3/5/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
1/22/2024	CARA Cara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$20.97M	1.80	N/A	N/A	$1.05 per share	0.66
PZA Invesco National AMT-Free Municipal Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$2.18	N/A	N/A	N/A	-565.21%	-122.10%	-89.64%	5/20/2024 (Estimated)
PZA Invesco National AMT-Free Municipal Bond ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CARA and PZA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/4/2024	12/31/2023	CARA Cara Therapeutics	-$0.57	-$0.59	-$0.02	-$0.59	$2.34 million	$3.00 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
PZA Invesco National AMT-Free Municipal Bond ETF	$0.62	2.64%	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.54	4.43
PZA Invesco National AMT-Free Municipal Bond ETF	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%
PZA Invesco National AMT-Free Municipal Bond ETF	N/A

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	4.20%
PZA Invesco National AMT-Free Municipal Bond ETF	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	55	54.66 million	52.36 million	Optionable
PZA Invesco National AMT-Free Municipal Bond ETF	N/A	116.25 million	N/A	Not Optionable

CARA and PZA Headlines

Source	Headline
	Invesco California AMT-Free Municipal Bond ETF declares monthly distribution of $0.0660 msn.com - March 19 at 10:20 AM
	iShares National Muni Bond ETF declares monthly distribution of $0.2682 msn.com - March 4 at 3:54 PM
	iShares Short-Term National Muni Bond ETF declares monthly distribution of $0.1805 msn.com - March 4 at 3:54 PM
	Investing With Impact: How Municipal Bonds Are Leading The Way seekingalpha.com - March 1 at 7:53 AM
	Invesco National AMT-Free Municipal Bond ETF thestreet.com - February 20 at 8:21 PM
	Invesco California AMT-Free Municipal Bond ETF declares monthly distribution of $0.0647 msn.com - February 20 at 10:21 AM
	Invesco California AMT-Free Municipal Bond ETF declares monthly distribution of $0.0610 msn.com - November 22 at 8:11 AM
	Invesco National AMT-Free Municipal Bond ETF declares monthly distribution of $0.0622 msn.com - November 22 at 8:11 AM
	Invesco New York AMT-Free Municipal Bond ETF thestreet.com - November 18 at 11:37 PM
	PZA ETF Stock Price History investing.com - November 4 at 10:36 PM
	Invesco California AMT-Free Municipal Bond ETF (PWZ) finance.yahoo.com - November 4 at 12:35 PM
	Invesco BulletShares 2027 Municipal Bond ETF declares monthly distribution of $0.0542 msn.com - August 21 at 12:11 PM
	Invesco New York AMT-Free Municipal Bond ETF (PZT) investing.com - August 4 at 6:41 PM
	Invesco New York AMT-Free Municipal Bond ETF declares monthly distribution of $0.0543 msn.com - July 24 at 7:03 PM
	Equity ETFs attract net inflows while conventional equity funds suffer redemptions opalesque.com - June 30 at 7:16 AM
	Invesco New York AMT-Free Municipal Bond ETF declares monthly distribution of $0.0550 msn.com - June 20 at 5:38 PM
	Invesco New York AMT-Free Municipal Bond ETF declares monthly distribution of $0.0546 msn.com - May 22 at 6:38 PM
	Invesco National AMT-Free Municipal Bond ETF declares monthly distribution of $0.0585 seekingalpha.com - May 22 at 6:38 PM
	Invesco California AMT-Free Municipal Bond ETF declares monthly distribution of $0.0581 msn.com - April 24 at 9:01 PM
	Vanguard Launches First ETF in Nearly 2 Years finance.yahoo.com - March 13 at 6:50 PM
	Invesco National AMT-Free Municipal Bond ETF declares monthly distribution of $0.0566 msn.com - February 20 at 12:44 PM
	Invesco AMT-Free Municipal Y morningstar.com - February 19 at 7:21 AM
	Invesco New York AMT-Free Municipal Bond ETF declares monthly distribution of $0.0525 msn.com - January 25 at 7:52 PM
	Invesco National AMT-Free Municipal Bond ETF declares monthly distribution of $0.0564 msn.com - January 25 at 7:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cara Therapeutics

NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Invesco National AMT-Free Municipal Bond ETF

NYSEARCA:PZA

The Invesco National AMT-Free Municipal Bond ETF (PZA) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund tracks an index of investment grade, tax-exempt debt publicly issued by a US state with at least 15 years remaining to maturity. PZA was launched on Oct 11, 2007 and is managed by Invesco.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial